Serum Periostin Is Associated With Fracture Risk in Postmenopausal Women: A 7-Year Prospective Analysis of the OFELY Study

Purpose:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture ris...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 99; no. 7; pp. 2533 - 2539
Main Authors Rousseau, J. C., Sornay-Rendu, E., Bertholon, C., Chapurlat, R., Garnero, P.
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.07.2014
Copyright by The Endocrine Society
Subjects
Online AccessGet full text
ISSN0021-972X
1945-7197
1945-7197
DOI10.1210/jc.2013-3893

Cover

Loading…
Abstract Purpose:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown.Subjects and Methods:Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.Results:At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1–3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < −2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4–21.8) after adjustment for age.Conclusion:High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment.
AbstractList Purpose:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown.Subjects and Methods:Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.Results:At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1–3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < −2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4–21.8) after adjustment for age.Conclusion:High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment.
PURPOSE:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown. SUBJECTS AND METHODS:Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured. RESULTS:At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1–3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < −2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4–21.8) after adjustment for age. CONCLUSION:High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment.
Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown.PURPOSEPeriostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown.Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.SUBJECTS AND METHODSSerum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1-3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < -2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4-21.8) after adjustment for age.RESULTSAt baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1-3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < -2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4-21.8) after adjustment for age.High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment.CONCLUSIONHigh serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment.
Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown. Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured. At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1-3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < -2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4-21.8) after adjustment for age. High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment.
Author Chapurlat, R.
Garnero, P.
Sornay-Rendu, E.
Rousseau, J. C.
Bertholon, C.
AuthorAffiliation INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), Université de Lyon, and Service de Rhumatologie et Pathologie Osseuse (R.C.), Hôpital E.-Herriot, Université de Lyon, 69437 Lyon Cedex 03, France; and Cisbio Bioassays (P.G.), 30200 Codolet, France
AuthorAffiliation_xml – name: INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), Université de Lyon, and Service de Rhumatologie et Pathologie Osseuse (R.C.), Hôpital E.-Herriot, Université de Lyon, 69437 Lyon Cedex 03, France; and Cisbio Bioassays (P.G.), 30200 Codolet, France
Author_xml – sequence: 1
  givenname: J. C.
  surname: Rousseau
  fullname: Rousseau, J. C.
  email: jean-charles.rousseau@inserm.fr
  organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France
– sequence: 2
  givenname: E.
  surname: Sornay-Rendu
  fullname: Sornay-Rendu, E.
  organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France
– sequence: 3
  givenname: C.
  surname: Bertholon
  fullname: Bertholon, C.
  organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France
– sequence: 4
  givenname: R.
  surname: Chapurlat
  fullname: Chapurlat, R.
  organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France
– sequence: 5
  givenname: P.
  surname: Garnero
  fullname: Garnero, P.
  organization: 1INSERM Research Unit 1033 (J.C.R., E.S.-R., C.B., R.C., P.G.), 69437 Lyon Cedex 03, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24628551$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1rGzEQxUVJaZy0t56LoIf20E31uavtzYQ4DRhimpY0J6HIs1jOerXVR4P710euk0sgAjEM_N4Mek9H6GDwAyD0npITyij5urYnjFBecdXyV2hCWyGrhrbNAZoQwmjVNuz3ITqKcU0IFULyN-iQiZopKekE_buCkDd4AcH5mNyALyKexuitMwmW-NqlFZ4FY1MOgH-4eIcLsyjoBgY_mhxNj699ab7hKW6qGzABL4KPI9jk_gKeDqbfRhex73BaAb6cnc1v8FXKy-1b9LozfYR3j_UY_Zqd_Tz9Xs0vzy9Op_PK8rYmlQGyhJY3RhkqFe06sJRBJwgQo0TH20Z0shTZKCMVobK1TW1UTaUkXNFbfow-7-eOwf_JEJPeuGih780APkdNpRCc0ZbIgn58hq59DuUJUXNaF_NUzVmhPjxS-XYDSz0GtzFhq59cLQDbA7Y4EQN02rpkkvNDCsb1mhK9i06vrd5Fp3fRFdGXZ6KnuS_gYo_f-z5BiHd9voegV2D6tNKkHFE3qioCQZrSVeVyUmSf9jKfx5cW_P9K_AEvy7My
CitedBy_id crossref_primary_10_1002_mus_26195
crossref_primary_10_1016_j_bone_2019_07_019
crossref_primary_10_1007_s00774_020_01200_3
crossref_primary_10_1111_jcpe_12432
crossref_primary_10_1007_s11914_020_00601_7
crossref_primary_10_1016_j_bone_2015_08_014
crossref_primary_10_3389_fmed_2023_1276900
crossref_primary_10_1007_s12020_015_0803_7
crossref_primary_10_1055_a_2053_8090
crossref_primary_10_1161_CIRCGEN_120_003258
crossref_primary_10_1007_s10238_018_0532_3
crossref_primary_10_1016_j_hrtlng_2020_04_017
crossref_primary_10_3390_cancers15235562
crossref_primary_10_1016_j_jbspin_2015_01_023
crossref_primary_10_1007_s00198_015_3442_1
crossref_primary_10_1016_j_rhum_2016_08_009
crossref_primary_10_1007_s00508_018_1386_0
crossref_primary_10_1016_j_bone_2014_05_016
crossref_primary_10_1093_rheumatology_kev410
crossref_primary_10_3803_EnM_2016_31_3_400
crossref_primary_10_1038_bcj_2016_90
crossref_primary_10_1097_MCO_0000000000000210
crossref_primary_10_1007_s00198_016_3839_5
crossref_primary_10_1016_j_bone_2017_03_041
crossref_primary_10_1016_j_metabol_2017_03_017
crossref_primary_10_1002_jbmr_3203
crossref_primary_10_3390_genes13030439
crossref_primary_10_1007_s12018_015_9185_x
crossref_primary_10_1111_odi_13664
crossref_primary_10_1007_s13277_015_3386_2
crossref_primary_10_3390_ijms25179159
crossref_primary_10_2147_IJGM_S335296
crossref_primary_10_1016_j_bone_2019_04_023
crossref_primary_10_1007_s00198_017_4272_0
crossref_primary_10_3803_EnM_2016_31_3_454
crossref_primary_10_1007_s40618_017_0820_x
crossref_primary_10_1007_s40291_017_0272_1
crossref_primary_10_1016_j_cca_2018_03_009
crossref_primary_10_1007_s10549_020_05570_0
crossref_primary_10_1016_j_bone_2019_01_004
crossref_primary_10_1210_jc_2017_00283
crossref_primary_10_1080_09603123_2022_2163989
crossref_primary_10_1016_j_joca_2015_05_015
crossref_primary_10_1007_s00198_017_4034_z
crossref_primary_10_1007_s00223_017_0302_3
crossref_primary_10_3390_nu16050605
crossref_primary_10_1080_17474086_2017_1283213
crossref_primary_10_3390_biomedicines11020603
crossref_primary_10_3803_EnM_2020_35_1_55
crossref_primary_10_1007_s00198_021_06018_x
crossref_primary_10_1530_EC_18_0186
crossref_primary_10_1210_clinem_dgz259
crossref_primary_10_1021_acs_jproteome_8b00637
crossref_primary_10_1007_s00223_018_0444_y
crossref_primary_10_1007_s12020_015_0735_2
crossref_primary_10_1093_nutrit_nuab061
Cites_doi 10.1007/s00223-012-9642-1
10.1016/j.bone.2004.09.004
10.1016/j.humpath.2008.07.008
10.1359/jbmr.2002.17.5.826
10.1172/JCI40973
10.1128/MCB.24.9.3992-4003.2004
10.1161/01.ATV.0000149141.81230.c6
10.1074/jbc.M109.060335
10.1128/MCB.25.24.11131-11144.2005
10.1016/S8756-3282(00)00325-2
10.3109/07435800.2013.794425
10.1002/ijc.25591
10.1007/s00441-007-0439-x
10.1023/A:1021899904332
10.1007/s00198-011-1861-1
10.1007/s001980200068
10.1359/jbmr.2000.15.8.1526
10.1369/jhc.7A7321.2007
10.1074/jbc.M708029200
10.1002/dvdy.10453
10.1359/jbmr.1999.14.7.1239
10.1371/journal.pone.0031974
10.1073/pnas.1203085109
10.1007/s00198-011-1892-7
10.1007/s00198-010-1501-1
10.1210/jc.2003-030964
10.1359/JBMR.050609
10.1002/jbmr.5650110307
10.1093/ndt/gfr670
10.1359/jbmr.1997.12.4.683
10.1016/j.jbspin.2011.05.004
10.1359/jbmr.090831
10.1016/S0925-4773(01)00356-2
10.1016/S0272-6386(03)00905-3
10.1002/jbmr.5650080915
ContentType Journal Article
Copyright Copyright © 2014 by the Endocrine Society 2014
Copyright © 2014 by The Endocrine Society
Copyright © 2014 by the Endocrine Society
Copyright_xml – notice: Copyright © 2014 by the Endocrine Society 2014
– notice: Copyright © 2014 by The Endocrine Society
– notice: Copyright © 2014 by the Endocrine Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TM
H94
K9.
7X8
DOI 10.1210/jc.2013-3893
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts


MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage 2539
ExternalDocumentID 24628551
10_1210_jc_2013_3893
00004678-201407000-00030
10.1210/jc.2013-3893
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations France
GeographicLocations_xml – name: France
GroupedDBID ---
-~X
.55
.XZ
08P
0R~
18M
1TH
29K
2WC
34G
354
39C
4.4
48X
53G
5GY
5RS
5YH
8F7
AABZA
AACZT
AAIMJ
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
ABBLC
ABDFA
ABEJV
ABGNP
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPMR
ABPPZ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ACGFO
ACGFS
ACPRK
ACUTJ
ACYHN
ADBBV
ADGKP
ADGZP
ADHKW
ADQBN
ADRTK
ADVEK
AELWJ
AEMDU
AENEX
AENZO
AETBJ
AEWNT
AFCHL
AFFZL
AFGWE
AFOFC
AFRAH
AFXAL
AGINJ
AGKRT
AGQXC
AGUTN
AHMBA
AHMMS
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
ARIXL
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BSWAC
BTRTY
C45
CDBKE
CS3
D-I
DAKXR
DIK
E3Z
EBS
EJD
EMOBN
ENERS
F5P
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
HZ~
H~9
KBUDW
KOP
KQ8
KSI
KSN
L7B
M5~
MHKGH
MJL
N9A
NLBLG
NOMLY
NOYVH
NVLIB
O9-
OAUYM
OBH
OCB
ODMLO
OFXIZ
OGEVE
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
P6G
REU
ROX
ROZ
TEORI
TJX
TLC
TR2
TWZ
VVN
W8F
WOQ
X7M
YBU
YFH
YHG
YOC
YSK
ZY1
~02
~H1
.GJ
3O-
7X7
88E
8FI
8FJ
AAJQQ
AAKAS
AAPGJ
AAQQT
AAUQX
AAWDT
AAYJJ
ABDPE
ABUWG
ABXZS
ACFRR
ACVCV
ACZBC
ADMTO
ADNBA
ADZCM
AEMQT
AEOTA
AERZD
AFFNX
AFFQV
AFKRA
AFYAG
AGMDO
AGORE
AHGBF
AI.
AJBYB
AJDVS
ALXQX
APJGH
AQDSO
AQKUS
AVNTJ
BENPR
BPHCQ
BVXVI
CCPQU
EIHJH
FEDTE
FYUFA
HMCUK
HVGLF
IAO
IHR
INH
ITC
J5H
M1P
MBLQV
N4W
NU-
OBFPC
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
TMA
UKHRP
VH1
WHG
X52
ZGI
ZXP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7QP
7T5
7TM
H94
K9.
7X8
ID FETCH-LOGICAL-c3960-ae0de937a8a1581ffec12ef40e0a84f3974f5f39578a580159c76a861550381b3
ISSN 0021-972X
1945-7197
IngestDate Fri Jul 11 02:32:22 EDT 2025
Mon Jun 30 12:42:22 EDT 2025
Mon Jul 21 06:07:24 EDT 2025
Thu Apr 24 22:56:44 EDT 2025
Tue Jul 01 01:10:30 EDT 2025
Fri May 16 03:44:11 EDT 2025
Fri Feb 07 10:35:44 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3960-ae0de937a8a1581ffec12ef40e0a84f3974f5f39578a580159c76a861550381b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 24628551
PQID 3164458632
PQPubID 2046206
PageCount 7
ParticipantIDs proquest_miscellaneous_1544321905
proquest_journals_3164458632
pubmed_primary_24628551
crossref_citationtrail_10_1210_jc_2013_3893
crossref_primary_10_1210_jc_2013_3893
wolterskluwer_health_00004678-201407000-00030
oup_primary_10_1210_jc_2013-3893
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-July
PublicationDateYYYYMMDD 2014-07-01
PublicationDate_xml – month: 07
  year: 2014
  text: 2014-July
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2014
Publisher Oxford University Press
Copyright by The Endocrine Society
Publisher_xml – name: Oxford University Press
– name: Copyright by The Endocrine Society
References Simon ( key 2019041114010700100_B35) 2014; 39
Xiao ( key 2019041114010700100_B18) 2012; 23
National Kidney Foundation ( key 2019041114010700100_B22) 2003; 42
Chopin ( key 2019041114010700100_B7) 2012; 79
Kruzynska-Frejtag ( key 2019041114010700100_B15) 2001; 103
Sasaki ( key 2019041114010700100_B27) 2003; 77
Merle ( key 2019041114010700100_B10) 2012; 23
Bonnet ( key 2019041114010700100_B17) 2012; 109
Satirapoj ( key 2019041114010700100_B32) 2012; 27
Sornay-Rendu ( key 2019041114010700100_B2) 2005; 20
Rios ( key 2019041114010700100_B25) 2005; 25
Szulc ( key 2019041114010700100_B24) 2005; 36
Genant ( key 2019041114010700100_B23) 1993; 8
Bacchetta ( key 2019041114010700100_B31) 2010; 25
Contie ( key 2019041114010700100_B19) 2011; 128
Johnell ( key 2019041114010700100_B5) 2002; 13
Horiuchi ( key 2019041114010700100_B13) 1999; 14
Arlot ( key 2019041114010700100_B20) 1997; 12
Gillan ( key 2019041114010700100_B28) 2002; 62
Garnero ( key 2019041114010700100_B1) 2004; 4
Vasikaran ( key 2019041114010700100_B3) 2011; 22
Yoshiba ( key 2019041114010700100_B26) 2007; 330
Chapurlat ( key 2019041114010700100_B6) 2000; 27
Kruzynska-Frejtag ( key 2019041114010700100_B14) 2004; 229
Kim ( key 2019041114010700100_B36) 2012; 91
Coutu ( key 2019041114010700100_B9) 2008; 283
Lindner ( key 2019041114010700100_B30) 2005; 25
Shao ( key 2019041114010700100_B29) 2004; 24
Schulz ( key 2019041114010700100_B37) 2004; 89
Garnero ( key 2019041114010700100_B8) 2002; 17
Guerrot ( key 2019041114010700100_B33) 2012; 7
Hakuno ( key 2019041114010700100_B34) 2010; 120
Bonnet ( key 2019041114010700100_B16) 2009; 284
Garnero ( key 2019041114010700100_B4) 2000; 15
Zhu ( key 2019041114010700100_B12) 2008; 56
Garnero ( key 2019041114010700100_B21) 1996; 11
Kashima ( key 2019041114010700100_B11) 2009; 40
References_xml – volume: 91
  start-page: 370
  year: 2012
  ident: key 2019041114010700100_B36
  article-title: Aortic calcification and bone metabolism: the relationship between aortic calcification, BMD, vertebral fracture, 25-hydroxyvitamin D, and osteocalcin
  publication-title: Calcif Tissue Int
  doi: 10.1007/s00223-012-9642-1
– volume: 36
  start-page: 13
  year: 2005
  ident: key 2019041114010700100_B24
  article-title: Biochemical markers of bone formation reflect endosteal bone loss in elderly men—MINOS study
  publication-title: Bone
  doi: 10.1016/j.bone.2004.09.004
– volume: 40
  start-page: 226
  year: 2009
  ident: key 2019041114010700100_B11
  article-title: Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2008.07.008
– volume: 17
  start-page: 826
  year: 2002
  ident: key 2019041114010700100_B8
  article-title: Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.2002.17.5.826
– volume: 4
  start-page: 50
  year: 2004
  ident: key 2019041114010700100_B1
  article-title: Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women
  publication-title: J Musculoskelet Neuronal Interact
– volume: 120
  start-page: 2292
  year: 2010
  ident: key 2019041114010700100_B34
  article-title: Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents
  publication-title: J Clin Invest
  doi: 10.1172/JCI40973
– volume: 24
  start-page: 3992
  year: 2004
  ident: key 2019041114010700100_B29
  article-title: Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.24.9.3992-4003.2004
– volume: 25
  start-page: 77
  year: 2005
  ident: key 2019041114010700100_B30
  article-title: Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000149141.81230.c6
– volume: 284
  start-page: 35939
  year: 2009
  ident: key 2019041114010700100_B16
  article-title: The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.060335
– volume: 25
  start-page: 11131
  year: 2005
  ident: key 2019041114010700100_B25
  article-title: Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.25.24.11131-11144.2005
– volume: 27
  start-page: 283
  year: 2000
  ident: key 2019041114010700100_B6
  article-title: Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study
  publication-title: Bone
  doi: 10.1016/S8756-3282(00)00325-2
– volume: 39
  start-page: 1
  issue: 1
  year: 2014
  ident: key 2019041114010700100_B35
  article-title: Bone mineral density, vertebral fractures and body mass index in postmenopausal women with abdominal aortic calcification
  publication-title: Endocr Res
  doi: 10.3109/07435800.2013.794425
– volume: 128
  start-page: 352
  year: 2011
  ident: key 2019041114010700100_B19
  article-title: Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25591
– volume: 62
  start-page: 5358
  year: 2002
  ident: key 2019041114010700100_B28
  article-title: Periostin secreted by epithelial ovarian carcinoma is a ligand for α(V)β(3) and α(V)β(5) integrins and promotes cell motility
  publication-title: Cancer Res
– volume: 330
  start-page: 133
  year: 2007
  ident: key 2019041114010700100_B26
  article-title: Association of TIMP-2 with extracellular matrix exposed to mechanical stress and its co-distribution with periostin during mouse mandible development
  publication-title: Cell Tissue Res
  doi: 10.1007/s00441-007-0439-x
– volume: 77
  start-page: 245
  year: 2003
  ident: key 2019041114010700100_B27
  article-title: Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer
  publication-title: Breast Cancer Res Treat
  doi: 10.1023/A:1021899904332
– volume: 23
  start-page: 1877
  year: 2012
  ident: key 2019041114010700100_B18
  article-title: Association of CDX1 binding site of periostin gene with bone mineral density and vertebral fracture risk
  publication-title: Osteoporos Int
  doi: 10.1007/s00198-011-1861-1
– volume: 13
  start-page: 523
  year: 2002
  ident: key 2019041114010700100_B5
  article-title: Biochemical indices of bone turnover and the assessment of fracture probability
  publication-title: Osteoporos Int
  doi: 10.1007/s001980200068
– volume: 15
  start-page: 1526
  year: 2000
  ident: key 2019041114010700100_B4
  article-title: Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.2000.15.8.1526
– volume: 56
  start-page: 329
  year: 2008
  ident: key 2019041114010700100_B12
  article-title: Immunolocalization of Periostin-like factor and periostin during embryogenesis
  publication-title: J Histochem Cytochem
  doi: 10.1369/jhc.7A7321.2007
– volume: 283
  start-page: 17991
  year: 2008
  ident: key 2019041114010700100_B9
  article-title: Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M708029200
– volume: 229
  start-page: 857
  year: 2004
  ident: key 2019041114010700100_B14
  article-title: Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction
  publication-title: Dev Dyn
  doi: 10.1002/dvdy.10453
– volume: 14
  start-page: 1239
  year: 1999
  ident: key 2019041114010700100_B13
  article-title: Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.1999.14.7.1239
– volume: 7
  start-page: e31974
  year: 2012
  ident: key 2019041114010700100_B33
  article-title: Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0031974
– volume: 109
  start-page: 15048
  year: 2012
  ident: key 2019041114010700100_B17
  article-title: Regulation of β catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1203085109
– volume: 23
  start-page: 1199
  year: 2012
  ident: key 2019041114010700100_B10
  article-title: The multiple facets of periostin in bone metabolism
  publication-title: Osteoporos Int
  doi: 10.1007/s00198-011-1892-7
– volume: 22
  start-page: 391
  year: 2011
  ident: key 2019041114010700100_B3
  article-title: Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
  publication-title: Osteoporos Int
  doi: 10.1007/s00198-010-1501-1
– volume: 89
  start-page: 4246
  year: 2004
  ident: key 2019041114010700100_B37
  article-title: Aortic calcification and the risk of osteoporosis and fractures
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2003-030964
– volume: 20
  start-page: 1813
  year: 2005
  ident: key 2019041114010700100_B2
  article-title: Identification of osteopenic women at high risk of fracture: the OFELY study
  publication-title: J Bone Miner Res
  doi: 10.1359/JBMR.050609
– volume: 11
  start-page: 337
  year: 1996
  ident: key 2019041114010700100_B21
  article-title: Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
  publication-title: J Bone Miner Res
  doi: 10.1002/jbmr.5650110307
– volume: 27
  start-page: 2702
  year: 2012
  ident: key 2019041114010700100_B32
  article-title: Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfr670
– volume: 12
  start-page: 683
  year: 1997
  ident: key 2019041114010700100_B20
  article-title: Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.1997.12.4.683
– volume: 79
  start-page: 26
  year: 2012
  ident: key 2019041114010700100_B7
  article-title: Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis
  publication-title: Joint Bone Spine
  doi: 10.1016/j.jbspin.2011.05.004
– volume: 25
  start-page: 849
  year: 2010
  ident: key 2019041114010700100_B31
  article-title: Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.090831
– volume: 103
  start-page: 183
  year: 2001
  ident: key 2019041114010700100_B15
  article-title: Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation
  publication-title: Mech Dev
  doi: 10.1016/S0925-4773(01)00356-2
– volume: 42
  start-page: S1
  year: 2003
  ident: key 2019041114010700100_B22
  article-title: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
  publication-title: Am J Kidney Dis
  doi: 10.1016/S0272-6386(03)00905-3
– volume: 8
  start-page: 1137
  year: 1993
  ident: key 2019041114010700100_B23
  article-title: Vertebral fracture assessment using a semiquantitative technique
  publication-title: J Bone Miner Res
  doi: 10.1002/jbmr.5650080915
SSID ssj0014453
Score 2.3824348
Snippet Purpose:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice...
PURPOSE:Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice...
Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop...
SourceID proquest
pubmed
crossref
wolterskluwer
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2533
SubjectTerms Adult
Age
Aged
Aged, 80 and over
Bone Density
Bone mineral density
Bone strength
Bone turnover
Cell Adhesion Molecules - blood
Cohort Studies
Collagen (type I)
Dual energy X-ray absorptiometry
Female
Fractures
France - epidemiology
Hip
Humans
Middle Aged
Osteocalcin
Osteoporosis
Osteoporotic Fractures - blood
Osteoporotic Fractures - epidemiology
Periosteum
Post-menopause
Protein turnover
Risk assessment
Risk Factors
Vertebrae
Title Serum Periostin Is Associated With Fracture Risk in Postmenopausal Women: A 7-Year Prospective Analysis of the OFELY Study
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201407000-00030
https://www.ncbi.nlm.nih.gov/pubmed/24628551
https://www.proquest.com/docview/3164458632
https://www.proquest.com/docview/1544321905
Volume 99
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBATQnxTGMhI8FS5SmK7SXgbU8uG-FK1ie4pchLnAbZkaloh9vfxh3FnJ26COmnwEuXDSZTcz7473_3OhLz2uPJAiwRM8zhlIs85i1IZM535qRBhCErNZPl-nhyeiA8LuRgMfneyltardJxdbuWV_I9U4RzIFVmy_yBZ91A4AfsgX9iChGF7LRlDR8c8dnhVBT21HB3V7neDHfkNp1hnyILCIMEcc8ihDa7OixXCL9S6NpPlcGDp6SE7xao-X5dVS7_slSxBC_XLbPrx1OQe9qLBiLVOCQrHttRlXsGoVG7qPJ3rFaDurK1baCI96xq629rAaTw6GLs5H1w7-Rebw0PMxam78k4vcTK3yRdwp5FKgew8o1bm4-58hi9c7uuGX-CzODSLrIOGssNyLCQLfZvJ247bdmGlBp9hdxCWtrZGo9DhMN6qLMDbRWWBhSx9ztBy2yjFNhHgL13pMhjRd4L7k-9ZgncnePcNcjMAZwXVw_uFSzQCj7Wphdp8V0O_QO5U9909w6hHtuz4PLvkzs8K0yjqH4ZF0bGFju-Ru40TQ_ctIu-TgS4fkFufmjSNh-TSAJM6YNKjmm6ASRGYtAUmRWBSaNMHJjXAfEv3qYUl7cCStrCkVUEBltTAkhpYPiIns-nxwSFrFvlgGQfvmSnt5RpsZBUpX0Y-JjH5gS6Epz0ViQLMZVHIAqPJkZJgTsk4CycqwnA6BrlT_pjslFWpnxIqYpWChZtqHoHRmqtI6jQP4zAriizQkRiSUfuHk6ypgI8LsZwl26Q5JG9c6wtb-eWKdhSEdVUTZpvstZJMmt5YJ9wHV0RGEx4MySt3GQZ3jNipUkPvS7BUFgebwpND8sQiwL0oQFY5-DtDwnqQSCyBOjHeP5iiDDsZKHZbQYJ7z675Xc_J7U333CM7q-VavwADfJW-NPj-Ayct1PA
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Periostin+Is+Associated+With+Fracture+Risk+in+Postmenopausal+Women%3A+A+7-Year+Prospective+Analysis+of+the+OFELY+Study&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Rousseau%2C+J.+C.&rft.au=Sornay-Rendu%2C+E.&rft.au=Bertholon%2C+C.&rft.au=Chapurlat%2C+R.&rft.date=2014-07-01&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=99&rft.issue=7&rft.spage=2533&rft.epage=2539&rft_id=info:doi/10.1210%2Fjc.2013-3893&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_jc_2013_3893
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon